Researchers at University College London and University College London Hospitals reported follow-up results from NEOPRISM-CRC, a trial testing a short course of immunotherapy before surgery for a subset of bowel cancer patients. The study is positioned as an attempt to deepen response while keeping the perioperative workflow intact. The new readout reported “zero relapses” in the follow-up period, an outcome that would be notable in a setting where perioperative immunotherapy is still being defined and patient selection remains a key question. The NEOPRISM-CRC strategy is designed to bypass longer, conventional sequencing by delivering systemic immune priming prior to tumor resection. Clinically, perioperative trial designs are increasingly used to generate tissue and response biology that can help refine future immunotherapy combinations and biomarkers. UCL and UCLH said the results support continued evaluation of the pre-surgery approach.